Cargando…
Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains
BACKGROUND: There is currently a requirement for antiviral therapies capable of protecting against infection with Venezuelan equine encephalitis virus (VEEV), as a licensed vaccine is not available for general human use. Monoclonal antibodies are increasingly being developed as therapeutics and are...
Autores principales: | O'Brien, Lyn M, Underwood-Fowler, Cindy D, Goodchild, Sarah A, Phelps, Amanda L, Phillpotts, Robert J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783036/ https://www.ncbi.nlm.nih.gov/pubmed/19925641 http://dx.doi.org/10.1186/1743-422X-6-206 |
Ejemplares similares
-
Improved Efficacy of a Gene Optimised Adenovirus-based Vaccine for Venezuelan Equine Encephalitis Virus
por: Williams, Amanda J, et al.
Publicado: (2009) -
Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs
por: O’Brien, Lyn
Publicado: (2007) -
Tumour Necrosis Factor-α, Chemokines, and Leukocyte Infiltrate Are Biomarkers for Pathology in the Brains of Venezuelan Equine Encephalitis (VEEV)-Infected Mice
por: Phelps, Amanda L., et al.
Publicado: (2023) -
Endemic Venezuelan Equine Encephalitis in Northern Peru
por: Aguilar, Patricia V., et al.
Publicado: (2004) -
Venezuelan Equine Encephalitis Virus, Southern Mexico
por: Estrada-Franco, José G., et al.
Publicado: (2004)